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Abstract
BACKGROUND AND AIMS: Circulating tumor cells (CTCs) have been proposed as a monitoring tool in patients with
solid tumors. So far, automated approaches are challenged by the cellular heterogeneity of CTC, especially
the epithelial-mesenchymal transition. Recently, Yu and colleagues showed that shifts in these cell popula-
tions correlated with response and progression, respectively, to chemotherapy in patients with breast cancer. In this
study, we assessed which non-hematopoietic cell types were identifiable in the peripheral blood of hepatocellular
carcinoma (HCC) patients and whether their distribution during treatment courses is associated with clinical charac-
teristics.METHODS: Subsequent to few enrichment steps, cell suspensions were spun onto glass slides and further
characterized using multi-immunofluorescence staining. All non-hematopoietic cells were counted and individual cell
profiles were analyzed per patient and treatment. RESULTS:Wedetected a remarkable variation of cells with epithelial,
mesenchymal, liver-specific, and mixed characteristics and different size ranges. The distribution of these subgroups
varied significantly between different patient groups and was associated with therapeutic outcome. Kaplan-Meier log-
rank test showed that a change in the ratio of epithelial tomesenchymal cells was associatedwith longer median time
to progression (1 vs 15 months; P= .03; hazard ratio = 0.18; 95% confidence interval = 0.01–2.75). CONCLUSIONS:
Our data suggest that different CTC populations are identifiable in peripheral blood of HCC patients and, for the first
time in HCC, that these individual cell type profiles may have distinct clinical implications. The further characterization
and analysis of patients in this ongoing study seems to be warranted.
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Introduction
Hepatocellular carcinoma (HCC) is associated with a poor prognosis
and is among the five most common malignancies worldwide with an
increasing incidence [1,2]. Curative therapeutic options are limited
to early stages and include mostly resection or orthotopic liver trans-
plantation if patients present with cirrhosis [3,4]. High recurrence
rates after resection and liver transplantation, most likely because
of minimal residual disease [5,6], and the fact that the majority of
patients are diagnosed in an advanced stage make palliative, often
localized approaches including selective internal radiation therapy
and transcatheter arterial chemoembolization necessary [7,8]. Up to
now, there are no reliable early markers of relapse or response to
surgical or interventional therapy. Serum-based markers like alpha-
fetoprotein (AFP), des-gamma-carboxyprothrombin, or the lectin 3
fraction of AFP (AFP-L3) are incapable of predicting the clinical out-
come with high accuracy and reproducibility [9]. Tissue-derived
molecular markers lack the possibility of monitoring the patient during
or after treatment, because this would require repeated biopsies and
hence increased risks for the patient. Therefore, the development of
minimally invasive diagnostic methods is necessary.
Circulating tumor cell (CTC), detected in the peripheral blood
of HCC patients, may represent a possible solution for this diag-
nostic dilemma. Though these cells have been frequently described
in breast and lung cancers [10–12], only few studies reported on
CTC in HCC patients using indirect methods like quantitative real-
time reverse transcription–polymerase chain reaction or direct visuali-
zation of circulating epithelial cells [13–17]. The main obstacle to
the broad clinical application of available automated CTC detection
methods is the high plasticity and variability of these cells among
others due to the epithelial-mesenchymal transition (EMT) as has
been very recently shown by Yu and colleagues in breast cancer [18].
In this ongoing study, we wanted to scrutinize the hypothesis that
a large variety of circulating non-hematopoietic cells exist in the pe-
ripheral blood of patients with HCC and that these cell types change
during treatment and whether these changes may implicate resistance
to therapy.
Materials and Methods
Study Population and Informed Consent
Patients with solid malignancies that received anticancer treatment
in our hospital were consecutively included in this study after agree-
ing and signing a written informed consent in accordance with the
requirements of our institution’s board of ethics (Internal Reference
No. 12-5047-BO). For this feasibility study, we tested the first 11 patients
with a follow-up of at least 6 months. There were no inclusion criteria
besides evaluable progression time and either being resected or receiv-
ing local ablative or systemic treatment. Patients with watch and wait
were assessed but not included in outcome-related statistics at the
time being. The clinicopathologic data of the patients used for CTC
quantification is listed in Table 1.
Blood Samples
Twenty milliliters of citrated peripheral blood from HCC patients
was drawn during treatment visits in the outpatient unit of our liver
tumor center, stored at room temperature, and processed within
24 hours after collection. We employed a negative selection strategy
to enrich and detect CTC. Hematopoietic cells were depleted using
anti-CD45 immunomagnetic beads leading to a bead-free cell sus-
pension that was then used for CTC type detection by immuno-
fluorescence staining against various epithelial [e.g., pan-cytokeratin
(pan-CK)] and mesenchymal markers (e.g., vimentin, N-cadherin).
Cell Culture and Spiking Experiments
HCT 116 and HepG2 cell lines were obtained from American
Culture Type Collection (ATCC, Rockville, MD) and maintained
according to ATCC guidelines. For method validation, we used
20 ml of peripheral blood from healthy donors spiked with 100
HCT 116 cells. Spiked blood samples were processed using density
gradient centrifugation and immunomagnetic enrichment strategy as
described below. HepG2 cells were mixed with peripheral blood
mononuclear cells (PBMNCs) from healthy donors and served as posi-
tive and negative controls for immunofluorescence staining. Gastro-
intestinal stromal tumor cells GIST 882 were a kind gift from Dr Bauer
(Department of Medical Oncology, University Hospital Essen).
Aliquots of GIST 882 cells were washed, resuspended in phosphate-
buffered saline (PBS), and spotted onto glass slides for subsequent
immunofluorescence staining against mesenchymal markers.
Sample Preparation
Isolation of PBMNCs using density gradient centrifugation.
Twenty milliliters of citrated peripheral blood was diluted with 10 ml
of PBS and poured into a Leucosep tube (Greiner Bio-One, Fricken-
hausen, Germany) prepared with 16-ml Ficoll-Paque (GE Healthcare,
Buckinghamshire, Great Britain) below the porous barrier. After density
gradient centrifugation at 1600g at 20°C for 20 minutes without brake,
the PBMNCs containing interphase above the barrier were transferred
into a new tube, washed with 50 ml of PBS containing 0.5% BSA,
and centrifuged at 300g at 20°C for 10 minutes. Subsequently, the
supernatant was removed completely.
Table 1. Patient Demographics for Quantification.
Demographic Patients (n = 11)
No. %
Tumor size (mm)
Median 49
Range 30–170
Child status
A 9 82
B 2 18
Cirrhosis 7 64
Chronic hepatic viral infection
HBV 2 18
HCV 4 36
Age
Median, years 70
Range 42–85
Therapy
Watch and wait 3 27
Selective internal radiation therapy 5 45
Transcatheter arterial chemoembolization 1 9
Resection 1 9
Nexavar 1 9
Response
Stable disease 4 36
Progressive disease 4 36
Time to progression (months)
Median 3
Range 0–19
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Tumor cell enrichment using immunomagnetic beads. Washed
PBMNCs were resuspended in 1 ml of PBS containing 0.1% BSA
and incubated with 25 μl of anti-CD45–coated immunomagnetic
Dynabeads (Invitrogen, Carlsbad, CA) for 30 minutes. Hematopoietic
cells except erythrocytes, platelets, and their precursor cells were bound
to beads and separated by a magnetic particle processor (King Fisher
mL; Thermo Fisher, Waltham, MA). The remaining cell suspension
included bead-free pre-enriched tumor cells and was spun onto two
glass slides per sample using the Cell Spin II centrifuge (Tharmac,
Waldsolms, Germany), air dried, and subsequently fixated with 96%
ethanol. Slides were stored at 4°C until subjected to immunocyto-
chemical staining. For assessment of the depletion rate, PBMNCs were
stained with trypan blue and enumerated using an automated cell
counter (Countess; Invitrogen) before and after immunomagnetic
separation. The results indicated an average CD45 depletion of
73%. By increasing the concentration of immunomagnetic beads,
the depletion rate could be increased up to 95%, though with an
increasing damage in respect to cell morphology.
Identification of Spiked HCT 116 Cells after Density Gradient
Centrifugation and Immunomagnetic Enrichment Using
Immunocytochemical Labeling
Detection of HCT 116 cells was performed using the Epimet kit
(Micromet, Munich, Germany). The identification of epithelial cells
is based on the reactivity of the murine monoclonal antibody (mAb)
A45-B/B3, directed against a common epitope of CK polypeptides.
The kit uses Fab fragments of the pan-mAb conjugated with alkaline
phosphatase molecules. The method includes permeabilization of the
cells by a detergent (5 minutes), fixation by a formaldehyde-based
solution (10 minutes), binding of the conjugate mAb A45-B/B3–
alkaline phosphatase to cytoskeletal CK (45 minutes), and formation
of an insoluble red reaction product at the binding site of the specific
conjugate (15 minutes). Subsequently, the cells were counterstained
with Mayer’s hematoxylin for 1 minute and finally mounted with
Kaiser’s glycerin/gelatin (Merck, Darmstadt, Germany) in Tris-EDTA
buffer (Sigma, Deisenhofen, Germany). A conjugate of Fab fragment
served as a negative control. For each test, a positive control slide with
the colon carcinoma cell line HCT 116 was treated under the same
conditions. The microscopic evaluation was carried out using the
ARIOL System (Applied Imaging, Newcastle upon Tyne, United
Kingdom) in the Department of Gynecology and Obstetrics (Essen,
Germany) according to the International Society of Hematotherapy
and Graft Engineering (ISHAGE) evaluation criteria and the dissemi-
nated tumor cells (DTC) consensus [19,20]. This automated scanning
microscope and image analysis system consists of a slide loader, camera,
computer, and software for the detection and classification of cells of
interest based on particular color, intensity, size, pattern, and shape.
Identification of CTC Subtypes Using
Multifluorescence Labeling
Immunofluorescence staining of epithelial, mesenchymal, liver-
derived, and hematopoietic cells was carried out in the CD45-depleted
pre-enriched tumor cell suspension. Briefly, the stainingmethod included
fixation of the cells in 4.5% paraformaldehyde for 15 minutes, washing
in PBS, permeabilization with 1× Perm/Wash Buffer (BD Biosciences,
Franklin Lakes, NJ) for 10 minutes, washing in PBS, blocking of un-
specific antibody reactions by incubation with blocking solution contain-
ing 5% BSA for 30 minutes, binding of primary antibodies (final
concentration, 5 μg/ml) either ASGPR1 rabbit mAb (ab42488; Abcam,
Cambridge, United Kingdom) or pan-CK guinea pig polyclonal anti-
body (ABIN126062, antibodies-online) and epithelial cell adhesion
molecule (EpCAM, E144) rabbit mAb (ab32392; Abcam) or vimentin
(EPR3776) rabbit mAb (2707-1; Epitomics, Burlingame, CA) or
N-cadherin (EPR1792Y) rabbit mAb (2019-1; Epitomics) for CTCs
and anti-CD45 (MEM-28) mouse mAb (ab8216; Abcam) for hemato-
logic cells overnight at 4°C, washing in 0.1% Tween, binding of second-
ary antibodies (fluorescein isothiocyanate–conjugated AffiniPure goat
anti-rabbit and Cy3-conjugated AffiniPure goat anti-mouse or Alexa
Fluor 647–conjugated AffiniPure F(ab′)2 fragment goat anti-guinea
pig; Jackson ImmunoResearch, Hamburg, Germany) for 30 minutes at
37°C, and washing in 0.1%Tween. Subsequently, cells were stained with
4′6-diamidino-2-phenylindole dihydrochloride (DAPI; Sigma-Aldrich,
St Louis, MO) for 10 minutes, mounted with anti-fading medium
(Invitrogen), and stored in the dark until evaluation. For each test, a posi-
tive control slide with a mixture of human PBMNCs and the HCC cell
line HepG2 was treated under the same conditions. Gastrointestinal
stromal cells (GIST 882) were used as positive control for mesenchy-
mal markers. Microscopic evaluation was carried out using the digital
Keyence BZ9000 (Biorevo, Osaka, Japan) all-in-one fluorescence
microscope with integrated camera and BZ-Analyzer Software. We used
Figure 1. (A) Cultured HCT 116 cells were harvested, washed, and spun onto glass slides using the Cell Spin II centrifuge. Subsequently,
they served as positive control for immunocytochemical staining against pan-CK (pink) using alkaline phosphatase. (B) Manual microscopic
detection of spiked HCT 116 cells in peripheral blood from healthy donors enriched with density gradient centrifugation and negative
enrichment through anti-CD45 immunomagnetic beads and stained against pan-CK. Pan-CK–positive cells are pink. Little brown round
particles are immunomagnetic beads. (C) Detection of spiked HCT 116 cells using the ARIOL-SL automated scanning system resulted
in a recovery rate of 100% after density gradient centrifugation and 43% after depletion of hematopoietic cells using anti-CD45–coated
immunomagnetic beads. (D) Detection of pan-CK–positive cell in peripheral blood from HCC patient using the ARIOL-SL System.
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pseudocolors to depict cells. Stained slides were manually examined and
CTCs were detected within the same areas, each consisting of 10 visual
fields using a ×20 magnification on both slides. Samples from five
healthy donors were processed and examined under the same conditions
to define a cutoff value for false-positive events.
Statistical Analysis
Statistical tests were performed according to previously published
studies by our group [21–23]. Spearman rank correlation was used
to examine associations between CTC subtypes and clinical charac-
teristics of the patients. Associations of the cell type ratios and time
to progression (TTP) were tested by the Kaplan-Meier method. Sur-
vival differences between patients with high and low cell type ratios
were analyzed by the log-rank test. The level of significance was set to
P < .05. All P values were based on two-sided tests. All statistical analy-
ses were performed using the Software Packages SPSS for Windows
(Version 19.0; SPSS Inc, Chicago, IL) and Medcalc, Version 12.3.0
(Mariakerke, Belgium).
Results
Enrichment Procedure
Analysis of the spiking experiments with 20 ml of whole blood
and 100 epithelial HCT 116 cells using the automated scanning
Figure 2. (A) Positive control consisting of PBMNCs mixed with HepG2 cells; stained against DAPI (blue) and epithelial or liver-specific
markers: pan-CK (red) and CD45 (green); EpCAM (yellow) and CD45 (green); ASGPR1 (red) and CD45 (green). PBMNCs were positive for
CD45 (green) and HepG2 cells were positive for pan-CK (red); EpCAM (yellow) and ASGPR1 (red). (B) CTC isolated from HCC patients
stained against DAPI (blue) and pan-CK (red)/CD45 (green) and EpCAM (yellow)/CD45 (green) and ASGPR1 (red)/CD45 (green). Cells
marked with a white arrow were considered as CTCs. They showed a DAPI-positive (blue)/CD45-negative staining and were positive
for pan-CK (red) or EpCAM (yellow) or ASGPR1 (red).
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microscope ARIOL-SL revealed a recovery rate of 100% after density
gradient centrifugation. Subsequent depletion with immunomagnetic
beads led to a significant lower recovery rate of 45% (Figure 1, A–C).
Furthermore, we were able to detect CK-positive cells in the peripheral
blood of HCC patients using this detection system (Figure 1D).
Immunofluorescence-based Identification of CTC Subtypes
For the investigation of cellular subtypes, a multistaining method
was required to detect various epithelial, mesenchymal, and hemato-
poietic markers and to characterize different cell types. Therefore, we
used multifluorescence staining for CTC subtype detection in HCC
patients. A mixture of PBMNCs from a healthy donor spiked with
epithelial cells from the HCC cell line HepG2 was used as positive
control and negative control. Hematopoietic cells showed positive
staining against CD45, whereas HepG2 cells were CD45-negative.
HepG2 cells stained positive against the epithelial markers pan-CK
and EpCAM and against the liver-specific ASGPR1 (Figure 2A).
When examining samples from HCC patients, objects that showed
a positive nuclear staining with DAPI, a negative staining for CD45,
and a positive staining against pan-CK, EpCAM, or ASGPR1 were
captured and considered as tumor cells (Figure 2B). We used GIST
882 cells as positive control for staining against the mesenchymal
markers N-cadherin and vimentin (Figure 3A). In HCC blood sam-
ples, we detected cells with mesenchymal features such as N-cadherin+/
CD45− and vimentin+/CD45− after negative isolation. We also de-
tected cells showing both epithelial and mesenchymal characteristics
such as N-cadherin+/CK+/CD45− and vimentin+/CK+/CD45− (Fig-
ure 3, B and C ). In addition, we found cells that stained positive for
potential markers of CTC and CD45 such as pan-CK+/EpCAM+/
CD45+ as well as pan-CK+/EpCAM−/CD45+ cells (Figure 4A [24]).
CTC profiles of each patient were examined and a ratio of mesenchymal
to epithelial cells was conceived (Figure 4B). Although we detected a
variety of cellular subtypes, we chose to summarize the total amount of
N-cadherin–positive and vimentin-positive/CD45-negative cells in
proportion to the total amount of CK-positive cells, respectively, after
negative enrichment using CD45 depletion. We normalized the enu-
merated potential CTC against the total PBMNC number detected in
the DAPI channel in each visual field and expressed the number of
CTC per 1000 PBMNCs (Figure 4C). Analysis of samples from healthy
donors revealed a cutoff for false-positive events at six CK-positive, one
N-cadherin–positive, and two vimentin-positive/CD45-negative cells
per 1000 PBMNCs after CD45 depletion.
Subtypes and Clinical Outcome
Spearman rank test resulted in a by trend significant association of
TTP with the N-cadherin+/CK+ ratio (P = .06) and the vimentin+/
CK+ ratio (P = .07), whereas there was no significant correlation of
TTP of the total amount of CK-positive, N-cadherin–positive, and
vimentin-positive cells. The total amount of N-cadherin–positive and
vimentin-positive cells was associated to the amount of CK-positive
cells (P = .05 and P = .1). Interestingly, 7 of 11 patients had cirrhosis,
but there was no association to TTP (P = .18). Though, the total
amount of CK-positive cells showed a by trend significant correlation
to cirrhosis (P = .1; Figure 5A) and the ratio of N-cadherin+/CK+ cells
Figure 3. (A) Immunofluorescence staining of GIST 882 cells as positive control for N-cadherin (yellow) and vimentin (yellow), respectively.
(B) Overlay picture of a CTC from an HCC patient showing both epithelial and mesenchymal features. This cell stained positive for pan-CK
(red), N-cadherin (green), and DAPI (blue). (C) CTC subtypes showing mesenchymal and/or epithelial features.
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was significantly correlated to cirrhosis (P = .03; Figure 5B). The amount
of epithelial CK+ cells (P = .1) and the ratio of N-cadherin+/CK+
cells (P = .1) showed a by trend significant correlation to the Child
status (Figure 5C).
To test whether the N-cadherin+/CK+ ratio or the vimentin+/CK+
ratio potentially divided patients according to their chance of a pro-
longed TTP, we used the Kaplan-Meier log-rank test, resulting in a
significant association of both ratios with TTP. A vimentin+/CK+
ratio higher than 0.5, meaning that there were half as many vimentin-
positive cells as CK+ cells, was associated with a longer median TTP
[1 vs 15 months; P = .03; hazard ratio (HR) = 0.18; 95% confidence
interval = 0.01–2.75]. A N-cadherin+/CK+ ratio lower than 0.1 re-
sembled an association to shortened TTP (1 vs 15 months; P = .03;
HR = 0.19; 95% confidence interval = 0.01–2.75; Figure 5D).
Discussion
In this study, we used multi-immunofluorescence staining to detect
a significant variety in interindividual as well as intraindividual CTC
characteristics. We measured epithelial cells, staining positive for
pan-CK (+DAPI) but negative for EpCAM, and CD45 as well as
cells staining positive for both CK and EpCAM while negative for
CD45. We also detected CTC with mesenchymal properties such as
vimentin and N-cadherin as well as cells with both epithelial and
mesenchymal features, remarkably with changing ratios even during
local ablative treatment of patients. It has very recently been described
by Yu and colleagues that CTC undergo EMT during treatment and
that these changes, and not only the absolute numbers of certain sub-
groups, correlate well with response and resistance to cytotoxic treat-
ment, respectively [25]. The detection of CTC showing mesenchymal
phenotype was also reported by Gradilone and colleagues who char-
acterized CTC for CK and markers of EMT and found the gain of
mesenchymal markers in CTC to be correlated to patient prognosis
in a follow-up of 24 months [26,27]. Their data showed that the pres-
ence of mesenchymal markers on CTC more accurately predicted a
poor prognosis than the expression of CK alone. Here, we were able
to confirm that the presence of mesenchymal cells correlates to survival
in HCC patients. However, our results in this study group indicated
that an increase in epithelial cells was associated with worse treatment
outcome in patients with HCC, which leads us to hypothesize that
epithelial cells may be the driver of aggressiveness in this study popu-
lation. Supporting these findings, we also revealed that the total
amount of CK+ cells was higher in patients with cirrhosis and in
patients with a worse Child status. These contradicting results may
be explainable by the different entities (breast vs hepatocellular cancer),
different treatment approaches, or a limited sample size. The shift
from mesenchymal to epithelial cell profiles was significantly correlated
with shortened TTP in both N-cadherin and vimentin to CK ratios,
respectively, and indicated that our data might be valid despite the
low patient number.
Figure 4. (A) Cells considered to be CTCs are indicated with a white arrow. This figure depicts the heterogeneity of detected CTC in one
single HCC blood sample. Among hematopoietic CD45-positve cells, it shows two CTCs that were both pan-CK–positive (red) and
CD45-positive (green), while one of them was also EpCAM-positive (yellow). All cells showed a positive nuclear staining (DAPI, blue).
(B) Example of individual morphologic profile showing one epithelial (CK-positive) and three mesenchymal (N-cadherin–positive) cells.
(C) CTC subtypes were summarized, normalized against the total amount of cells in the DAPI channel per visual field, and expressed in
potential CTC per 1000 PBMNCs after enrichment.
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Remarkably, in our study, epithelial and mesenchymal cells were
detectable in the peripheral blood of almost all patients—in different
proportions—whereas only some of these patients (4/11; 36%) pre-
sented cells with both features on the same cell potentially indicating
different stages of EMT. However, this patient group is too small
to answer this question conclusively at this point. Additionally, a
distinct proportion of cells stained positive for pan-CK and CD45
as well as for EpCAM, pan-CK, and CD45, a phenomenon already
described by Yu and colleagues [24]. The additional CD45+ staining
may not be exclusive for hematopoietic cells but may hypothetically
be acquired during dormant stay in the bone marrow or through
effects comparable to trogocytosis, i.e., transfer of membrane pro-
teins [28]. Therefore, depletion of CD45-positive cells might lead
to a loss of cells of interest during the negative enrichment proce-
dure. Moreover, the retrieval was significantly lower after immuno-
magnetic depletion compared to density gradient centrifugation alone
as shown by our spiking experiments. Though when anticipating
CTC isolation from blood recapturing spiked cultured cells it remains
unclear to which extent these experiments reflect the in vivo situation.
CD45 depletion will be omitted in the following studies to obtain an
increased CTC recovery rate. After determining the total amount of
cells, samples will be spun onto the required amount of slides with
maximum of 5 × 106 cells per slide that will lead to a higher number
of slides with increased staining options allowing to investigate a
wider range of cell type characteristics. Even though the depletion
rate was not very effective, we chose to proceed with the protocol to
diminish hematopoietic cells and to be able to overlook different cell
types within blood samples. Moreover, our method is based on cell
type ratios rather than absolute cell numbers assuming that a loss
of potential CTC might not affect the proportion of their CD45-
negative subtypes. These questions need to be addressed in sub-
sequent investigations analyzing a higher number of blood samples
and multiple CTC subtypes also including endothelial, stem cell,
and other characteristics.
Figure 5. (A) The total amount of CK+ cells/1000 PBMNCs was higher in patients with cirrhosis compared to patients without cirrhosis
(P = .1). (B) The ratio of N-cadherin+/CK+ cells was also correlated to cirrhosis. Patients with cirrhosis had a higher total amount of
CK+ cells that led to a lower ratio of N-cadherin+/CK+ cells compared to patients without cirrhosis (P = .03). (C) The ratio of N-cadherin+/
CK+ cells was correlated to the Child status (P= .1). (D) Association of high vs low N-cadherin+/CK+ CTC ratio with TTP employing Kaplan-
Meier log-rank test (P = .03; HR = 0.18).
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In contrast to CTC in other entities being commonly described
to have a large cellular size and a high nuclear to cytoplasmic ratio
[14], our results confirm a previous report from a patient with breast
cancer by Marrinucci and colleagues showing a wide range of signal
intensities and a variety of cell sizes [29,30]. This is of relevance
because the isolation by size of epithelial tumor cells using the ISET
System (Rarecells, Paris, France) is one of the few major (semi)
automated approaches used for detecting CTC. Vona et al. used
ISET in patients with HCC to evaluate its clinical impact. Fifty-
two percent of a total of 44 patients had detectable CTC and their
prevalence was significantly correlated with the presence of multi-
focal tumors, portal tumor thrombosis, and Child-Pugh class B/C
[15]. In a study of Schulze and colleagues, the CellSearch System
was applied to detect EpCAM-positive CTC in the blood of HCC
patients resulting in a detection rate of 45% (14 of 31 HCC patients)
and a significant correlation between the detection of epithelial
CTC and pathologic AFP values [17]. Xu et al. reported the devel-
opment and validation of an EpCAM-independent magnetic cell
separation system mediated by the interaction of the ASGPR1 exclu-
sively expressed on hepatocytes with its ligand. CTCs were then
identified by Hep-Par-1 staining. An average of 24 ± 19 CTCs per
5 ml of blood was detected in 81% of HCC patients, suggesting that
the variation ranged from one to nine tumor cells per milliliter in
the examined patients. Therefore, with this study, we wanted to
show that the individual cell composition and especially changes in
this personal cell profile implicate alternating therapeutic responses,
potentially with more sensitivity than currently available. Further-
more, these changes may lead to specific treatments, aiming at distinct
CTC profiles.
Taken together, our data support the hypothesis that different
CTC populations are identifiable in the peripheral blood of patients
with HCC and that these individual cell type profiles may have dis-
tinct clinical implications. This method offers an opportunity to detect
changes in the composition of circulating non-hematopoietic cells in
the blood of patients with HCC and, therefore, to create an individual
profile of each patient, which might help to predict patient outcome
and potentially to select the appropriate treatment. Further studies
including systemic treatments of HCC seem to be warranted.
Acknowledgments
We thank Sabine Kasimir-Bauer and her team (Department of Gyne-
cology and Obstetrics, University Hospital Essen) for supporting the
validation of our method using the ARIOL-SL System. We also thank
Karl Lang (Institute of Immunology, University Hospital Essen) for
constantly granting us access to his Keyence all-in-one fluorescence
microscope. Furthermore, we thank Sebastian Bauer and his team
(Department of Medical Oncology, University Hospital Essen) for
the supply of GIST 882 cells.
References
[1] Llovet JM, Burroughs A, and Bruix J (2003). Hepatocellular carcinoma. Lancet
362, 1907–1917.
[2] Jemal A, Bray F, Center MM, Ferlay J, Ward E, and Forman D (2011). Global
cancer statistics. CA Cancer J Clin 61, 69–90.
[3] Belghiti J, Panis Y, Farges O, Benhamou JP, and Fekete F (1991). Intrahepatic
recurrence after resection of hepatocellular carcinoma complicating cirrhosis.
Ann Surg 214, 114–117.
[4] Arriagada R, Bergman B, Dunant A, Le Chevalier T, Pignon JP, and Vansteenkiste J
(2004). Cisplatin-based adjuvant chemotherapy in patients with completely
resected non–small-cell lung cancer. N Engl J Med 350, 351–360.
[5] Winton T, Livingston R, Johnson D, Rigas J, Johnston M, Butts C, Cormier Y,
Goss G, Inculet R, Vallieres E, et al. (2005). Vinorelbine plus cisplatin vs. obser-
vation in resected non–small-cell lung cancer. N Engl J Med 352, 2589–2597.
[6] Olaussen KA, Dunant A, Fouret P, Brambilla E, André F, Haddad V,
Taranchon E, Filipits M, Pirker R, Popper HH, et al. (2006). DNA repair
by ERCC1 in non–small-cell lung cancer and cisplatin-based adjuvant chemo-
therapy. N Engl J Med 355, 983–991.
[7] Sangro B, Bilbao JI, Boan J, Martinez-Cuesta A, Benito A, Rodriguez J, Panizo A,
Gil B, Inarrairaegui M, Herrero I, et al. (2006). Radioembolization using
90Y-resin microspheres for patients with advanced hepatocellular carcinoma.
Int J Radiat Oncol Biol Phys 66, 792–800.
[8] Lau WY, Lai EC, and Leung TW (2011). Current role of selective internal
irradiation with yttrium-90 microspheres in the management of hepatocellular
carcinoma: a systematic review. Int J Radiat Oncol Biol Phys 81, 460–467.
[9] Sun YF, Yang XR, Zhou J, Qiu SJ, Fan J, and Xu Y (2011). Circulating tumor
cells: advances in detection methods, biological issues, and clinical relevance.
J Cancer Res Clin Oncol 137, 1151–1173.
[10] Lianidou ES and Markou A (2011). Circulating tumor cells in breast cancer:
detection systems, molecular characterization, and future challenges. Clin Chem
57, 1242–1255.
[11] Hou JM, Krebs M, Ward T, Sloane R, Priest L, Hughes A, Clack G, Ranson M,
Blackhall F, and Dive C (2011). Circulating tumor cells as a window on metas-
tasis biology in lung cancer. Am J Pathol 178, 989–996.
[12] Zhang N, Li X, Wu CW, Dong Y, Cai M, Mok MT, Wang H, Chen J,
Ng SS, Chen M, et al. (2012). microRNA-7 is a novel inhibitor of YY1 con-
tributing to colorectal tumorigenesis. Oncogene. DOI: 10.1038/onc.2012.526,
E-pub ahead of print.
[13] Waguri N, Suda T, Nomoto M, Kawai H, Mita Y, Kuroiwa T, Igarashi M,
Kobayashi M, Fukuhara Y, and Aoyagi Y (2003). Sensitive and specific detection
of circulating cancer cells in patients with hepatocellular carcinoma; detection of
human telomerase reverse transcriptase messenger RNA after immunomagnetic
separation. Clin Cancer Res 9, 3004–3011.
[14] Xu W, Cao L, Chen L, Li J, Zhang XF, Qian HH, Kang XY, Zhang Y, Liao J,
Shi LH, et al. (2011). Isolation of circulating tumor cells in patients with hepato-
cellular carcinoma using a novel cell separation strategy. Clin Cancer Res 17,
3783–3793.
[15] Vona G, Estepa L, Beroud C, Damotte D, Capron F, Nalpas B, Mineur A,
Franco D, Lacour B, Pol S, et al. (2004). Impact of cytomorphological de-
tection of circulating tumor cells in patients with liver cancer. Hepatology 39,
792–797.
[16] Guo J, Yao F, Lou Y, Xu C, Xiao B, Zhou W, Chen J, Hu Y, and Liu Z (2007).
Detecting carcinoma cells in peripheral blood of patients with hepatocellular
carcinoma by immunomagnetic beads and RT-PCR. J Clin Gastroenterol 41,
783–788.
[17] Schulze K, Beneken C, Staufer K, Nashan B, Lohse AW, Pantel K, Riethdorf S,
and Wege H (2011). Detection of Epcam-positive circulating tumor cells in
patients with hepatocellular carcinoma—a pilot study. Hepatology 54, 1357a.
[18] Krebs MG, Hou JM, Sloane R, Lancashire L, Priest L, Nonaka D, Ward TH,
Backen A, Clack G, Hughes A, et al. (2012). Analysis of circulating tumor cells
in patients with non-small cell lung cancer using epithelial marker-dependent
and -independent approaches. J Thorac Oncol 7, 306–315.
[19] Ignatiadis M, Georgoulias V, and Mavroudis D (2008). Circulating tumor cells
in breast cancer. Curr Opin Obst Gynecol 20, 55–60.
[20] Ignatiadis M, Georgoulias V, and Mavroudis D (2008). Micrometastatic disease
in breast cancer: clinical implications. Eur J Cancer 44, 2726–2736.
[21] Hoffmann A-C (2009). A three-gene signature for outcome in soft tissue sarcoma.
Clin Cancer Res 15, 6472.
[22] Hoffmann A-C, Mori R, Vallbohmer D, Brabender J, Klein E, Drebber U, Baldus
SE, Cooc J, Azuma M, Metzger R, et al. (2008). High expression of HIF1a is a
predictor of clinical outcome in patients with pancreatic ductal adenocarcinomas
and correlated to PDGFA, VEGF, and bFGF. Neoplasia 10, 674–679.
[23] Hoffmann A-C, Wild P, Leicht C, Bertz S, Danenberg KD, Danenberg PV,
Stoehr R, Stoeckle M, Lehmann J, Schuler M, et al. (2010). MDR1 and
ERCC1 expression predict outcome of patients with locally advanced bladder
cancer receiving adjuvant chemotherapy. Neoplasia 12, 628–636.
[24] Yu M, Stott S, Toner M, Maheswaran S, and Haber DA (2011). Circulating
tumor cells: approaches to isolation and characterization. J Cell Biol 192,
373–382.
[25] Yu M, Bardia A, Wittner BS, Stott SL, Smas ME, Ting DT, Isakoff SJ,
Ciciliano JC, Wells MN, Shah AM, et al. (2013). Circulating breast tumor cells
Translational Oncology Vol. 6, No. 4, 2013 Circulating Tumor Cell Profiles in Liver Cancer Nel et al. 427
exhibit dynamic changes in epithelial and mesenchymal composition. Science
339, 580–584.
[26] Gradilone A, Raimondi C, Nicolazzo C, Petracca A, Gandini O, Vincenzi B,
Naso G, Agliano AM, Cortesi E, and Gazzaniga P (2011). Circulating tumour
cells lacking cytokeratin in breast cancer: the importance of being mesenchymal.
J Cell Mol Med 15, 1066–1070.
[27] Raimondi C, Gradilone A, Naso G, Vincenzi B, Petracca A, Nicolazzo C,
Palazzo A, Saltarelli R, Spremberg F, Cortesi E, et al. (2011). Epithelial-
mesenchymal transition and stemness features in circulating tumor cells from
breast cancer patients. Breast Cancer Res Treat 130, 449–455.
[28] Joly E and Hudrisier D (2003). What is trogocytosis and what is its purpose?
Nat Immunol 4, 815.
[29] Allard WJ, Matera J, Miller MC, Repollet M, Connelly MC, Rao C, Tibbe AG,
Uhr JW, and Terstappen LW (2004). Tumor cells circulate in the peripheral
blood of all major carcinomas but not in healthy subjects or patients with
nonmalignant diseases. Clin Cancer Res 10, 6897–6904.
[30] Marrinucci D, Bethel K, Bruce RH, Curry DN, Hsieh B, Humphrey M,
Krivacic RT, Kroener J, Kroener L, Ladanyi A, et al. (2007). Case study
of the morphologic variation of circulating tumor cells. Hum Pathol 38,
514–519.
428 Circulating Tumor Cell Profiles in Liver Cancer Nel et al. Translational Oncology Vol. 6, No. 4, 2013
